Peritoneal tunnels: A site at risk for treatment failure when performing treatments for peritoneal metastases. A case series of 2 patients

ConclusionsPeritoneal tunnels in the inguinal region or at the porta hepatis should be opened by surgical dissection so that all foci of peritoneal metastases are removed at a complete cytoreductive surgery and these sites treated with chemotherapy.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research

Related Links:

ConclusionsAbdominal wall defects from resection of cancerous masses of the abdominal wall can be closed with a contralateral rectus abdominis muscle transplant in the absence of mesh.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
ConclusionInitial tumor load has not been found associated with PFS after complete surgery. Adipocytes-enriched areas and right mesocolic areas involvement were associated with poor prognosis in patients receiving primary debulking surgery. Larger-scale studies are needed to assess whether initial tumor load has a prognostic impact even after complete cytoreductive surgery is achieved.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Patients with peritoneal mesothelioma undergoing a second cytoreductive surgery had a median survival of 92 months, according to a recent study at St. George Hospital and the University of South Wales in Sydney, Australia. That same group of patients also had a five-year survival rate of 71.8%, further illustrating the progress being made in treating the peritoneal subtype of this rare and aggressive cancer. The Journal of Surgical Oncology published the study in July 2019. The single-center study detailed the survival benefits of cytoreduction and perioperative intraperitoneal chemotherapy in colorectal, ovarian, appendic...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 10 August 2019Source: Gynecologic Oncology ReportsAuthor(s): Elizabeth K. Lee, Zhenying Tan-Wasielewski, Ursula A. Matulonis, Michael J. Birrer, Alexi A. Wright, Neil Horowitz, Panagiotis A. Konstantinopoulos, Jennifer Curtis, Joyce F. LiuAbstractPeripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore has demonstrated synergistic antitumor activity ...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
ConclusionsOnly 3.2% of patients developed a symptomatic respiratory complication following CRS and HIPEC. A pleural effusion was identified in almost all patients requiring a diaphragmatic peritonectomy as part of their CRS; however, less than one in ten of these patients required pleural drainage. Prophylactic insertion of a pleural drainage tube is, therefore, not indicated following CRS and HIPEC.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 31 July 2019Source: European Journal of Surgical OncologyAuthor(s): M. Yu Reutovich, O.V. Krasko, O.G. SukonkoAbstractBackgroundEvaluation of hyperthermic intraperitoneal chemotherapy (HIPEC) in reducing metachronous peritoneal metastases (MPM) risks in patients with resectable serosa-invasive gastric cancer.Materials &methodsBetween 2008 and 2016, 154 patients with gastric cancer (stage IIB-IIIC) were randomly assigned to two groups: 76 patients underwent HIPEC (cisplatin 50 mg/m2 + doxorubicin 50 mg/m2, 42 °C, 1 h) combined with radical surgery (HIPEC group)...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: Available online 30 July 2019Source: European Journal of Surgical OncologyAuthor(s): Oliver M. Fisher, Nayef A. Alzahrani, Mathew A. Kozman, Sarah J. Valle, Winston Liauw, David L. MorrisAbstractBackgroundMost studies on the effects of intraoperative packed red blood cell transfusions (iPRBT) on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown deleterious outcomes. It is unclear if this is a result of the transfusion itself or because iPRBTs serve as a surrogate of more advanced disease.MethodsA retrospective analysis of 880 patients treated ...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
AbstractPurposeCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS  + HIPEC) is the active treatment for peritoneal carcinomatosis of appendiceal origin. However, surgical management is sometimes difficult in patients with a high-tumor burden.MethodsA high-tumor burden was defined as a peritoneal cancer index (PCI)  ≥ 28. Among 49 patients receiving CRS + HIPEC, 29 had a PCI ≥ 28.ResultsComplete cytoreduction (CC-0/1) was achieved in 20 of the 29 patients with a PCI  ≥ 28 and in all 20 patients with a PCI 
Source: Surgery Today - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | Peritoneal Cancer | Surgery